[Current data on vigabatrin].
OBJECTIVE
We analyze the most usual pharmacokinetic and pharmacodynamic characteristics of vigabatrin, considering the current therapeutic indications which define its greatest usefulness in seizures and partial epileptic syndromes.


METHODS
At the same time, we assess the adverse effects described with special reference to peripheral changes in the visual field, although their mode of production is still unknown; similarly we describe the relevant hypotheses. We emphasize the usefulness of this drug in some seizures and epileptic syndromes, such as the infantile spasms of West's syndrome. Finally, we emphasize the need to establish an equilibrium between risks and benefits, so that this therapeutic option may still be used in spite of the risks, particularly when other options are not free of serious side-effects, as occurs with the corticosteroids or valproic acid at high doses.
Casas-Fernández
C
C
Sección de Neuropediatria, Hospital Universitario Virgen de la Arrixaca, Murcia, España. ccasas@forodigital.es
D000927:Anticonvulsants / Q000009:adverse effects*; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D020888:Vigabatrin / Q000009:adverse effects*; D014794:Visual Fields / Q000187:drug effects
D000927:Anticonvulsants; D020888:Vigabatrin